Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 599,965 |
|
|||||
| News | - | ||||||
| Day High | 12.61 | Low High |
|||||
| Day Low | 12.17 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nurix Therapeutics Inc | NRIX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -0.08% | 12.35 | 16:36:12 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12.49 | 12.17 | 12.61 | 12.35 | 12.36 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,667 | 599,965 | US$ 12.41 | US$ 7,442,596 | - | 4.22 - 18.12 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:13:44 | 17 | US$ 12.36 | USD |
Nurix Therapeutics (NRIX) Options Flow Summary
Nurix Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 603.84M | 48.89M | - | 76.99M | -143.95M | -2.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nurix Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRIX Price Data
| Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.33 | 14.84 | 12.17 | 13.43 | 794,646 | -1.98 | -13.82% |
| 1 Month | 14.69 | 18.12 | 12.17 | 15.21 | 1,361,424 | -2.34 | -15.93% |
| 3 Months | 8.15 | 18.12 | 7.84 | 13.52 | 1,050,062 | 4.20 | 51.53% |
| 6 Months | 4.27 | 18.12 | 4.22 | 11.04 | 885,786 | 8.08 | 189.23% |
| 1 Year | 10.09 | 18.12 | 4.22 | 10.35 | 614,221 | 2.26 | 22.40% |
| 3 Years | 30.94 | 37.425 | 4.22 | 15.02 | 480,017 | -18.59 | -60.08% |
| 5 Years | 20.25 | 52.38 | 4.22 | 17.61 | 446,176 | -7.90 | -39.01% |
Nurix Therapeutics Description
| Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
